Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Yoshihiro Kobashigawa, Yu Yaguchi, Rena Morooka, Kyo Okazaki, Ryota Omizu, Hiroyuki Kumeta, Hiroshi Morioka
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Cell signaling by receptor tyrosine kinases
10.1016/s0092-8674(00)00114-8 · 2000
Cell signaling by receptor tyrosine kinases
10.1016/j.cell.2010.06.011 · 2010
Receptor tyrosine kinases: legacy of the first two decades
10.1101/cshperspect.a008912 · 2014
Protein kinases — the major drug targets of the twenty-first century?
10.1038/nrd773 · 2002
Targeting cancer with small molecule kinase inhibitors
10.1038/nrc2559 · 2009
Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis
10.1021/acs.jmedchem.1c00963 · 2022
Rational design of inhibitors that bind to inactive kinase conformations
10.1038/nchembio799 · 2006
Comprehensive analysis of kinase inhibitor selectivity
10.1038/nbt.1990 · 2011
A biophysical framework for double-drugging kinases
10.1073/pnas.2304611120 · 2023
Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase
10.1073/pnas.1919221117 · 2020
Energetic dissection of Gleevec’s selectivity toward human tyrosine kinases
10.1038/nsmb.2891 · 2014
Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor
10.1016/s1097-2765(00)80357-3 · 1999
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase
10.1126/science.289.5486.1938 · 2000
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571)
2002
A Src-like inactive conformation in the abl tyrosine kinase domain
10.1371/journal.pbio.0040144 · 2006
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations
10.1158/0008-5472.can-08-3953 · 2009
Atomic view of the energy landscape in the allosteric regulation of Abl kinase
10.1038/nsmb.3470 · 2017
Conformational states dynamically populated by a kinase determine its function
10.1126/science.abc2754 · 2020
Fibroblast growth factor signalling: from development to cancer
10.1038/nrc2780 · 2010
Blocking of FGFR signaling inhibits breast cancer cell proliferation through down-regulation of D-type cyclins
10.1038/sj.onc.1207331 · 2004
Inhibition of endogenous SPARC enhances pancreatic cancer cell growth: modulation by FGFR1-III isoform expression
10.1038/sj.bjc.6605440 · 2010
Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression
10.1158/1078-0432.ccr-11-3214 · 2012
Expression of aFGF, bFGF, and FGFR1 in ovarian epithelial neoplasm
2004
Structural and dynamic insights into the energetics of activation loop rearrangement in FGFR1 kinase
10.1038/ncomms8877 · 2015
Experimental design for analysis of complex kinetics using surface plasmon resonance
10.1006/meth.1999.0924 · 2000
The effect of mutations on drug sensitivity and kinase activity of fibroblast growth factor receptors: a combined experimental and theoretical study
10.1016/j.ebiom.2015.02.009 · 2015
How does a drug molecule find its target binding site?
10.1021/ja202726y · 2011
Improvement of antibody affinity by introduction of basic amino acid residues into the framework region
2018
Arginine cluster introduction on framework region in anti-lysozyme antibody improved association rate constant by changing conformational diversity of CDR loops
10.1002/pro.4745 · 2023
Fluorine-containing FDA-approved small-molecule drugs in 2025: significance, synthetic insights, and therapeutic applications
10.1039/d6ra01711h · 2026
Which halogen to choose? Comparing the effects of chlorine and fluorine as bioisosteric substituents in drug design
10.1039/d5sc07348k · 2026
Structural analysis of the mechanism of phosphorylation of a critical autoregulatory tyrosine residue in FGFR1 kinase domain
10.1111/gtc.12277 · 2015
Nuclear magnetic resonance analysis of the conformational state of cancer mutant of fibroblast growth factor receptor 1 tyrosine kinase domain
10.1111/gtc.12345 · 2016
Biophysical characterization of drug-resistant mutants of fibroblast growth factor receptor 1
10.1111/gtc.12405 · 2016
A low-cost affinity purification system using β-1,3-glucan recognition protein and curdlan beads
10.1093/protein/gzs028 · 2012
Crystal structure of the C2 fragment of streptococcal protein G in complex with the fc domain of human IgG
10.1016/s0969-2126(01)00157-5 · 1995
Solution structure of the silkworm betaGRP/GNBP3 N-terminal domain reveals the mechanism for beta-1,3-glucan-specific recognition
10.1073/pnas.0901671106 · 2009
Comparative protein structure modeling using MODELLER
10.1002/cpbi.3 · 2016
UCSF chimera—a visualization system for exploratory research and analysis
10.1002/jcc.20084 · 2004
Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald
10.1021/ct400314y · 2013
Numerical integration of the Cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes
10.1016/0021-9991(77)90098-5 · doi-reference
An analysis of the accuracy of Langevin and molecular dynamics algorithms
10.1080/00268978800101881 · doi-reference
Molecular dynamics with coupling to an external Bath
10.1063/1.448118 · doi-reference
Fast, efficient generation of high-quality atomic charges. AM1-BCC model: II. Parameterization and validation
10.1002/jcc.10128 · doi-reference
A fast and high-quality charge model for the next generation general AMBER force field
10.1063/5.0019056 · doi-reference
ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB
10.1021/acs.jctc.5b00255 · doi-reference